MX2019000225A - Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.

Info

Publication number
MX2019000225A
MX2019000225A MX2019000225A MX2019000225A MX2019000225A MX 2019000225 A MX2019000225 A MX 2019000225A MX 2019000225 A MX2019000225 A MX 2019000225A MX 2019000225 A MX2019000225 A MX 2019000225A MX 2019000225 A MX2019000225 A MX 2019000225A
Authority
MX
Mexico
Prior art keywords
compositions
treatment
disease
autoimmune
methods
Prior art date
Application number
MX2019000225A
Other languages
English (en)
Inventor
D Eliasof Scott
Original Assignee
Cerulean Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerulean Pharma Inc filed Critical Cerulean Pharma Inc
Publication of MX2019000225A publication Critical patent/MX2019000225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan métodos que se relación con el uso conjugados de CDP-agente terapéutico para el tratamiento de la enfermedad autoinmune, enfermedad inflamatoria, o cáncer. Se proporcionan, además, conjugados de CDP-agente terapéutico, partículas que comprenden los conjugados de CDP-agente terapéutico, y composiciones que comprenden los conjugados de CDP-agente terapéutico.
MX2019000225A 2010-05-18 2012-11-09 Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. MX2019000225A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34564110P 2010-05-18 2010-05-18

Publications (1)

Publication Number Publication Date
MX2019000225A true MX2019000225A (es) 2019-05-15

Family

ID=44992046

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012013100A MX2012013100A (es) 2010-05-18 2011-05-18 Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MX2019000225A MX2019000225A (es) 2010-05-18 2012-11-09 Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012013100A MX2012013100A (es) 2010-05-18 2011-05-18 Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.

Country Status (10)

Country Link
US (1) US20110300150A1 (es)
EP (2) EP3566719A1 (es)
JP (2) JP5881254B2 (es)
CN (2) CN103037903A (es)
AU (2) AU2011255647A1 (es)
CA (2) CA2799202C (es)
EA (1) EA035193B1 (es)
IL (2) IL222800A0 (es)
MX (2) MX2012013100A (es)
WO (1) WO2011146638A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120104412A (ko) 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
JP2015505557A (ja) * 2012-01-31 2015-02-23 セルリアン・ファーマ・インコーポレイテッド 治療的送達のためのシクロデキストリンに基づく重合体
JP2015505559A (ja) * 2012-01-31 2015-02-23 セルリアン・ファーマ・インコーポレイテッド 治療剤送達のためのシクロデキストリン系ポリマー
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
NZ746440A (en) 2012-10-11 2019-11-29 Daiichi Sankyo Co Ltd Glycinamide derivatives and production methods thereof
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
CN103012672B (zh) * 2012-12-27 2014-08-06 西北师范大学 具有抗肿瘤活性的五氟尿嘧啶共聚物及其制备方法
WO2014161072A1 (en) * 2013-04-02 2014-10-09 The Governing Council Of The University Of Toronto Α-boryl isocyanides, boropeptides and boron heterocycles
SG11201509026VA (en) * 2013-05-02 2015-12-30 Hoffmann La Roche Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
WO2015095784A1 (en) * 2013-12-19 2015-06-25 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
EP3973995A1 (en) 2014-01-31 2022-03-30 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
JP6612738B2 (ja) 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
NZ722668A (en) 2014-04-10 2024-02-23 Daiichi Sankyo Europe Gmbh Anti-her3 antibody-drug conjugate
KR20180021723A (ko) 2015-06-29 2018-03-05 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 선택적 제조 방법
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
WO2018110515A1 (ja) 2016-12-12 2018-06-21 第一三共株式会社 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
MX2019008059A (es) 2017-01-17 2019-12-11 Daiichi Sankyo Co Ltd Anticuerpo anti-gpr20 y conjugado de anticuerpo-medicamento anti-gpr20.
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
CN111051330A (zh) 2017-08-31 2020-04-21 第一三共株式会社 抗体-药物缀合物的改进制备方法
CN111417410B (zh) 2017-12-01 2023-06-23 艾伯维公司 糖皮质激素受体激动剂及其免疫缀合物
EP3794041B1 (en) 2018-05-18 2023-07-12 Glycotope GmbH Anti-muc1 antibody
CN115109258A (zh) * 2021-03-19 2022-09-27 江西中医药大学 7-乙基-10-羟基喜树碱聚合物、制备方法及其应用

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
ES2058081T3 (es) 1986-09-05 1994-11-01 American Cyanamid Co Poliesteres que contienen bloques de oxido de alquileno como sistemas de administracion de medicamentos.
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
IE910713A1 (en) 1990-03-05 1991-09-11 Cephalon Inc Chymotrypsin-like proteases
FR2665169A1 (fr) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres.
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
EP1808183A3 (en) * 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JP3699141B2 (ja) * 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
ES2206607T3 (es) 1995-11-17 2004-05-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilones, preparacion y utilizacion.
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
CA2264908C (en) 1996-09-06 2006-04-25 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6280999B1 (en) 1998-01-23 2001-08-28 Kosan Bioscience Sorangium polyketide synthases and encoding DNA therefor
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
DE19848306A1 (de) 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
PT1140944E (pt) 1998-12-22 2004-01-30 Novartis Pharma Gmbh Derivados de epotilona e sua utilizacao como agentes antitumorais
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
SK11452001A3 (sk) 1999-02-11 2002-04-04 Schering Aktiengesellschaft Deriváty epotilónu, farmaceutický prípravok s ich obsahom a ich použitie
GEP20033067B (en) 1999-02-22 2003-09-25 Bristol Myers Squibb Co C-21 Modified Epothilones
CA2368658A1 (en) 1999-03-29 2000-10-05 Soong-Hoon Kim A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
WO2001007439A2 (en) 1999-07-22 2001-02-01 Schering Aktiengesellschaft Process for the production of epothiolone b and derivatives as well as intermediate products for this process
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
AU7662600A (en) 1999-10-08 2001-04-23 Novartis Ag 13-alkyl epothilone derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
WO2001074382A1 (en) 2000-03-31 2001-10-11 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
WO2001092255A2 (en) 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
AU7902501A (en) 2000-07-25 2002-02-05 Kosan Biosciences Inc Fermentation process for epothilones
AU2001283275A1 (en) 2000-08-09 2002-02-18 Kosan Biosciences, Inc. Bio-intermediates for use in the chemical synthesis of polyketides
DE10134172A1 (de) 2001-07-13 2003-01-23 Morphochem Ag Epothilone-Synthesebausteine IV:Unsymmetrisch substituierte Acyloine und Acyloinderivate und Verfahren zu deren Herstellung
DE10051136A1 (de) 2000-10-16 2002-04-18 Ludger A Wessjohann Epothilone-Synthesebausteine III und Verfahren zur Herstellung von Epothilon B, D und Epothilonderivaten
WO2002042432A2 (en) 2000-11-22 2002-05-30 Novartis Ag Epothilone resistant cell lines
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
SK288098B6 (sk) 2001-01-25 2013-07-02 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
EP3078667B1 (en) 2001-01-25 2018-11-21 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
KR20030071853A (ko) 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EE200300397A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaadid refraktaarsete kasvajate raviks
RU2003128311A (ru) 2001-02-20 2005-03-10 Бристол-Маерс Сквибб Компани (Us) Способ лечения резистентных опухолей с применением аналогов эпотилона
WO2002067941A2 (en) 2001-02-27 2002-09-06 Novartis Ag Combination comprising a signal transduction inhibitor and an epothilone derivative
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2002074042A2 (en) 2001-03-19 2002-09-26 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
PT1420780E (pt) 2001-08-23 2008-12-29 Novartis Ag Análogos ciclopropilados e ciclobutilados da epotilona
WO2003042217A2 (en) 2001-11-15 2003-05-22 Kosan Biosciences, Inc. Method for making epothilone compounds by bioconversion with microorganisms
WO2003045324A2 (en) 2001-11-26 2003-06-05 Kosan Biosciences, Inc. 14-methyl-epothilones
TWI287986B (en) 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
IL162595A0 (en) 2002-01-14 2005-11-20 Novartis Ag Combinations comprising epothilones and antimetabolites
AU2003239121A1 (en) 2002-02-22 2003-09-09 Insert Therapeutics, Inc. Carbohydrate-modified polymers, compositions and uses related thereto
ATE380861T1 (de) 2002-02-25 2007-12-15 Kosan Biosciences Inc Modulation der verteilung artverwandter sekundärer metaboliten
CN1939299A (zh) 2002-03-08 2007-04-04 诺瓦提斯公司 包含埃坡霉素衍生物和烷化剂的组合
US6719540B2 (en) 2002-03-12 2004-04-13 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
WO2003077903A1 (en) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
EP1503756B1 (en) 2002-05-01 2009-08-12 Novartis AG Epothilone derivative for the treatment of hepatoma and other cancer diseases
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
JP2006514681A (ja) 2002-05-20 2006-05-11 コーザン バイオサイエンシス インコーポレイテッド エポチロンｄの投与方法
US7119071B2 (en) 2002-05-21 2006-10-10 University Of Medicine And Dentistry Of New Jersey Amino terminal substance P compositions and methods for using the same
CN101816792A (zh) 2002-06-10 2010-09-01 诺瓦提斯公司 包含埃坡霉素的组合及其药学用途
DE10232094A1 (de) 2002-07-15 2004-02-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 5-Thiaepothilone und 15-disubstituierte Epothilone
PT1546152E (pt) 2002-08-02 2008-03-12 Scripps Research Inst Derivados de epotilona
EP1562627A4 (en) * 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
CA2892003A1 (en) * 2002-09-06 2004-03-18 Cerulean Pharma Inc. Modified cyclodextrin ring compounds having exactly two hydroxyl moieties substituted with an amino acid for therapeutics delivery
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
KR20120104412A (ko) * 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
GB0221312D0 (en) 2002-09-13 2002-10-23 Novartis Ag Organic compounds
US7091193B2 (en) 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
EP1549269A4 (en) * 2002-10-09 2010-10-06 Cerulean Pharma Inc CYCLODEXTRIN BASED MATERIALS, COMPOSITIONS AND ITS USE
MXPA05003706A (es) 2002-10-09 2005-07-01 Kosan Biosciences Inc Epo d+5-fu/gemcitabina.
GB0230024D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
AU2003219947A1 (en) 2003-02-26 2004-09-28 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
GB0305928D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
MXPA06003835A (es) 2003-10-09 2006-06-14 Kosan Biosciences Inc Formulaciones terapeuticas.
US20050203174A1 (en) 2004-03-09 2005-09-15 Kosan Biosciences, Inc. Combination therapies using leptomycin B
US20050215604A1 (en) 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
DK3385267T3 (da) 2004-03-30 2021-11-01 Millennium Pharm Inc Syntese af boronestere og syreforbindelser
US20090004277A1 (en) 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
CN1988904A (zh) 2004-07-26 2007-06-27 诺瓦提斯公司 埃坡霉素组合
ATE411053T1 (de) * 2004-08-09 2008-10-15 Deutsches Krebsforsch Albuminkonjugate, die eine glucuron-verknüpfung enthalten
JO2596B1 (en) 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
EP2325236A1 (en) 2005-04-20 2011-05-25 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
KR20090005310A (ko) 2006-04-05 2009-01-13 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
KR20090038902A (ko) 2006-08-16 2009-04-21 노파르티스 아게 에포틸론 ｂ의 결정 형태 및 제약 조성물에서의 용도
EP1930004A1 (en) 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Use of epothilones in the treatment of osteoporosis and related diseases
TWI528976B (zh) * 2006-12-13 2016-04-11 斯茹林製藥公司 用於醫物傳遞之以環糊精為基之聚合物
KR20090082486A (ko) 2006-12-14 2009-07-30 노파르티스 아게 항암성 약물로서 ｃ12-ｃ13 위치에서 개질된 에포틸론 유사체
JP2010516625A (ja) * 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US8030503B2 (en) 2007-05-11 2011-10-04 Kosan Biosciences Incorporated Process for the preparation of epothilones
EP2009114A1 (en) 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US8410305B2 (en) 2007-11-12 2013-04-02 Kosan Biosciences Incorporated Intermediates and methods for the preparation of epothilones
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
US20110152512A1 (en) * 2009-09-09 2011-06-23 John Ryan Cyclodextrin-based polymers for therapeutics delivery
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物

Also Published As

Publication number Publication date
EP2571525A4 (en) 2016-04-27
AU2015200791A1 (en) 2015-03-12
EP3566719A1 (en) 2019-11-13
CA2799202A1 (en) 2011-11-24
JP5881254B2 (ja) 2016-03-09
IL222800A0 (en) 2012-12-31
CA2927832C (en) 2021-03-23
CA2927832A1 (en) 2011-11-24
EP2571525A1 (en) 2013-03-27
CA2799202C (en) 2016-07-05
WO2011146638A1 (en) 2011-11-24
IL267014A (en) 2019-07-31
CN105797168A (zh) 2016-07-27
JP2013526549A (ja) 2013-06-24
CN103037903A (zh) 2013-04-10
JP2014196359A (ja) 2014-10-16
MX2012013100A (es) 2013-01-22
US20110300150A1 (en) 2011-12-08
EA035193B1 (ru) 2020-05-14
AU2011255647A1 (en) 2012-11-15
EA201201400A1 (ru) 2013-03-29

Similar Documents

Publication Publication Date Title
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
IN2012MN02591A (es)
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX2020012426A (es) Anticuerpos anti-cd38.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2012061390A3 (en) Therapeutic compositions and methods
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
IN2015MN00001A (es)
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
WO2011130697A3 (en) Tissue targeting
MX342239B (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.